Cargando…

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Detalles Bibliográficos
Autores principales:	Merchant, Mark, Moffat, John, Schaefer, Gabriele, Chan, Jocelyn, Wang, Xi, Orr, Christine, Cheng, Jason, Hunsaker, Thomas, Shao, Lily, Wang, Stephanie J., Wagle, Marie-Claire, Lin, Eva, Haverty, Peter M., Shahidi-Latham, Sheerin, Ngu, Hai, Solon, Margaret, Eastham-Anderson, Jeffrey, Koeppen, Hartmut, Huang, Shih-Min A., Schwarz, Jacob, Belvin, Marcia, Kirouac, Daniel, Junttila, Melissa R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785022/ https://www.ncbi.nlm.nih.gov/pubmed/29370292 http://dx.doi.org/10.1371/journal.pone.0192059

Ejemplares similares

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model
por: Kirouac, Daniel C., et al.
Publicado: (2017)

Erratum: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model
por: Kirouac, Daniel C., et al.
Publicado: (2017)

p21-activated kinase 1: PAK'ed with potential
por: Ong, Christy C., et al.
Publicado: (2011)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
por: Wagle, Marie-Claire, et al.
Publicado: (2018)

Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras
por: Lauchle, Jennifer O., et al.
Publicado: (2009)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
por: Ahn, Soomin, et al.
Publicado: (2017)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
por: Yoshioka, Ema, et al.
Publicado: (2018)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells
por: Jin, W, et al.
Publicado: (2003)

Mek1/2 Gene Dosage Determines Tissue Response to Oncogenic Ras Signaling in the Skin
por: Scholl, F A, et al.
Publicado: (2009)

The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA
por: Komatsu, Yumiko, et al.
Publicado: (2016)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer
por: Pfohl, Ulrike, et al.
Publicado: (2022)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Sanguisorba officinalis L. enhances the 5-fluorouracil sensitivity and overcomes chemoresistance in 5-fluorouracil-resistant colorectal cancer cells via Ras/MEK/ERK and PI3K/Akt pathways
por: Zhang, Weijia, et al.
Publicado: (2023)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease
por: Kirouac, Lisa, et al.
Publicado: (2017)

PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors
por: Schmidt, Enrico K, et al.
Publicado: (2004)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c2vsjk9mu3deg2v7co5mbm8faq